Type
|
Public |
---|---|
Traded as | NASDAQ: JUNO |
Industry | Biotechnology |
Founded | 2013 |
Headquarters | Seattle, WA |
Key people
|
Hans Bishop (CEO & President) |
Website | junotherapeutics |
Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)
Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.
In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. In June, the company announced it would acquire X-Body for more than $44 million. In June, the company announced a 10-year partnership with Celgene valued at $1 billion. As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.
In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets. Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million. This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.
2016-07-10 | Reiterated Rating | Maxim Group | Buy | $80.00 |
2016-07-10 | Reiterated Rating | Cowen and Company | Buy | $55.00 |
2016-07-09 | Reiterated Rating | FBR & Co | Buy | |
2016-07-08 | Reiterated Rating | Leerink Swann | Outperform | $60.00 |
2016-07-08 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $63.00 to $39.00 |
2016-07-08 | Lower Price Target | FBR & Co | Outperform | $73.00 to $61.00 |
2016-07-06 | Initiated Coverage | Barclays PLC | Equal Weight | $48.00 |
2016-06-06 | Reiterated Rating | FBR & Co. | Buy | |
2016-06-06 | Reiterated Rating | FBR & Co | Buy | |
2016-06-02 | Initiated Coverage | Raymond James | Outperform | $52.00 |
2016-06-02 | Initiated Coverage | Raymond James Financial Inc. | Outperform | $52.00 |
2016-05-10 | Reiterated Rating | FBR & Co. | Buy | |
2016-05-05 | Initiated Coverage | Cowen and Company | Outperform | $55.00 |
2016-04-20 | Reiterated Rating | SunTrust | Buy | $50.00 |
2016-04-20 | Reiterated Rating | SunTrust Banks Inc. | Buy | $50.00 |
2016-04-11 | Reiterated Rating | Maxim Group | Buy | $78.00 to $80.00 |
2016-04-09 | Reiterated Rating | FBR & Co. | Buy | $73.00 |
2016-04-08 | Boost Price Target | Morgan Stanley | $48.00 to $50.00 | |
2016-03-20 | Reiterated Rating | SunTrust | Buy | $50.00 |
2016-03-18 | Reiterated Rating | Leerink Swann | Outperform | $67.00 |
2016-03-02 | Lower Price Target | Leerink Swann | Outperform | $65.00 to $60.00 |
2016-03-02 | Reiterated Rating | FBR & Co. | Outperform | $73.00 |
2016-02-27 | Initiated Coverage | Deutsche Bank | Buy | |
2016-02-27 | Initiated Coverage | Deutsche Bank AG | Buy | |
2016-02-25 | Initiated Coverage | Citigroup Inc. | Buy | $45.00 |
2016-02-22 | Lower Price Target | Goldman Sachs | $50.00 to $41.00 | |
2016-02-22 | Lower Price Target | Goldman Sachs Group Inc. | $50.00 to $41.00 | |
2016-02-17 | Reiterated Rating | Maxim Group | Buy | $78.00 |
2016-02-17 | Upgrade | Guggenheim | Neutral to Buy | |
2016-01-28 | Initiated Coverage | SunTrust | Buy | $50.00 |
2016-01-13 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $69.00 |
2016-01-11 | Reiterated Rating | FBR & Co. | Buy | $73.00 |
2015-12-15 | Upgrade | Standpoint Research | Hold to Buy | |
2015-12-08 | Reiterated Rating | FBR & Co. | Outperform | $73.00 |
2015-11-30 | Reiterated Rating | Leerink Swann | Outperform | |
2015-11-18 | Initiated Coverage | Goldman Sachs | Neutral | $50.00 |
2015-11-11 | Boost Price Target | Leerink Swann | $56.00 to $65.00 | |
2015-11-11 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $70.00 to $69.00 |
2015-10-29 | Downgrade | Standpoint Research | Buy to Hold | |
2015-10-06 | Reiterated Rating | FBR & Co. | Outperform | $73.00 |
2015-09-16 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $70.00 |
2015-08-24 | Initiated Coverage | Standpoint Research | Buy | $47.00 |
2015-08-18 | Initiated Coverage | FBR & Co. | Outperform | $73.00 |
2015-08-17 | Lower Price Target | Morgan Stanley | $54.00 to $53.00 | |
2015-08-13 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $83.00 to $70.00 |
2015-08-04 | Reiterated Rating | Maxim Group | Buy | $78.00 |
2015-07-22 | Initiated Coverage | Northland Securities | Outperform | $64.00 |
2015-07-20 | Lower Price Target | Goldman Sachs | Neutral | $52.00 to $51.00 |
2015-06-30 | Lower Price Target | Morgan Stanley | Equal Weight | $59.00 to $54.00 |
2015-06-30 | Reiterated Rating | Maxim Group | Buy | |
2015-06-30 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $66.00 to $83.00 |
2015-06-18 | Initiated Coverage | Maxim Group | Buy | $78.00 |
2015-05-28 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $66.00 |
2015-05-14 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $66.00 |
2015-05-13 | Reiterated Rating | Leerink Swann | Outperform | $74.00 |
2015-04-06 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2015-03-19 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $66.00 |
2015-01-13 | Initiated Coverage | Leerink Swann | Outperform | $74.00 |
2015-01-13 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $66.00 |
2015-01-13 | Initiated Coverage | Goldman Sachs | Neutral | $52.00 |
2016-07-10 | Reiterated Rating | Maxim Group | Buy | $80.00 |
2016-07-10 | Reiterated Rating | Cowen and Company | Buy | $55.00 |
2016-07-09 | Reiterated Rating | FBR & Co | Buy | |
2016-07-08 | Reiterated Rating | Leerink Swann | Outperform | $60.00 |
2016-07-08 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $63.00 to $39.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In JUNO 14 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 2.15M |
BlackRock Institutional Trust Company, N.A. | 1.83M |
RS INVESTMENT MANAGEMENT CO LLC | 87958 |
BlackRock Group LTD | 64697 |
BLACKROCK ADVISORS LLC | 40017 |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38850 |
BlackRock Investment Management, LLC | 31662 |
Spot Trading L.L.C | 30053 |
SOUND ENERGY PARTNERS, INC. | 25800 |
RUSSELL FRANK CO/ | 17919 |
Numeric Investors LLC | 5410 |
MANAGED ACCOUNT ADVISORS LLC | 2483 |
ROCKEFELLER FINANCIAL SERVICES INC | 2407 |
ALPHAGEN SECURITIES LLC | 300 |